Analyst Update: Peabody Energy, Ambarella, aTyr Pharma

Analysts adjusted their ratings and price targets on Peabody Energy Corporation (NYSE:BTU), Ambarella Inc (NASDAQ:AMBA), and aTyr Pharma Inc (NASDAQ:LIFE)

Jun 1, 2015 at 1:31 PM
facebook X logo linkedin


Analysts are weighing in on coal concern Peabody Energy Corporation (NYSE:BTU), semiconductor specialist Ambarella Inc (NASDAQ:AMBA), and drugmaker aTyr Pharma Inc (NASDAQ:LIFE). Here's a quick roundup of today's brokerage notes on BTU, AMBA, and LIFE.

  • BTU has earned a dreary spot on the Big Board, after Goldman Sachs initiated coverage on the stock with a "sell" rating and a $2 price target, citing concerns over domestic thermal coal demand. At last check, the security was down 6.2% at $3.16, and fresh off a record low of $3.15. Today's negative price action just echoes the withstanding trajectory of a security that's surrendered 80% of its value year-over-year. Peabody Energy Corporation could encounter a fresh wave of selling pressure, too, should any analysts follow in Goldman Sachs' footsteps. Currently, seven out of 17 brokerage firms maintain a "buy" or better rating on the equity, while the average 12-month price target of $7.10 stands at a 125% premium to BTU's present perch.

  • Ahead of AMBA's turn in the earnings confessional tomorrow night, Deutsche Bank raised its price target on the stock to $80 from $64. The bullish brokerage note has sent the shares soaring to yet another record high; this time, with AMBA topping out at $93.86. Longer term, the stock has added 85% in 2015, and was last seen lingering near $93.73. In the options pits, speculators have shown an increasing preference for puts over calls among options set to expire in three months or less. Specifically, Ambarella Inc's Schaeffer's put/call open interest ratio (SOIR) has jumped to 1.10 from its May 18 reading of 0.94, and now ranks in the 66th percentile of its annual range.

  • Wall Street newcomer LIFE received a bevy of bullish brokerage notes, and has moved 2.1% higher to $23.36 as a result. Both BMO and William Blair, for example, initiated coverage with an "outperform" rating and a $42 price target. Elsewhere, J.P. Morgan Securities started the stock with an "overweight" recommendation and a $44 target price, while Citigroup began coverage with a "buy" suggestion and a $32 price target. Since going public on May 7, aTyr Pharma Inc has tacked on more than 75%, and topped out at a post-IPO peak of $27.82 on May 21.
 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI